New CAR-T therapy aims to tackle Hard-to-Treat lymphoma
NCT ID NCT07316920
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This early-stage study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or stopped responding to standard therapy. RN1701 uses specially engineered immune cells (CAR-T cells) from a donor to target and kill cancer cells. The main goals are to check if the treatment is safe and to see if it can shrink tumors. Up to 19 adults aged 18-75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.